Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
Status:
Completed
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in
participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This
is a two-part trial, with three panels per part. T1DM (Part 1) and T2DM (Part 2) participants
will be given daily fixed doses of MK-5160 in three predefined, increasing doses in each
panel, or glargine (active comparator). The primary hypothesis of the trial is that at a dose
with sufficient safety, the mean steady-state maximum level of glucose infusion rate (GIRmax)
after MK-5160 administration in both T1DM and T2DM participants is between 1.5 and 4.5
mg/kg/min.